Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Blood (2020) 135 (17): 1484–1496.

https://doi.org/10.1182/blood.2019001292

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 Repeat Dosing with BIVV001: The First Investigational Factor VIII Product to Break through the Von Willebrand Factor-Imposed Half-Life Ceiling

Toshko Lissitchkov, Kara Rice, Suresh Katragadda, Annemieke Willemze, Craig Benson, Karin Knobe

Blood (2019) 134 (Supplement_1): 625.

https://doi.org/10.1182/blood-2019-122211

Published: 2019

Journal Articles

Cryo-EM Structure of BIVV001 Reveals Coagulation Factor VIII-Von Willebrand Factor D'D3 Interaction Mode

James Fuller, PhD, Joseph Batchelor, PhD, Kevin Knockenhauer, PhD, Hans-Peter Biemann, PhD, Robert Peters

Blood (2019) 134 (Supplement_1): 94.

https://doi.org/10.1182/blood-2019-126645

Published: 2019

Journal Articles

Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein

Teresa Álvarez Roman, Elena Monzón Manzano, Ihosvany Fernandez-Bello, Mónica Martín, María Isabel Rivas Pollmar, Raul Justo Sanz, Sara García Barcenilla, Paula Acuña, Tamara Cebanu, Miguel A Canales, MD PhD, Nora Butta, PhD, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 4929.

https://doi.org/10.1182/blood-2019-127878

Published: 2019

Journal Articles

Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate — Recombinant Factor VIII Fc (Eloctate™) — a Report from India

Aby Abraham, MD DM, Shashikant Apte, MD FRCPA, Chandrakala Shamukhaiah, MD DM, Fouzia N., DNB, DM, Kannan Subramaniam, DNB, DM, Akshata Rahate, MD DM, Abraham Sunder Singh, BSc, Aditi Joshi, BAMS, Kavitha M Lakshmi, MSc, Rajesh Phatale, MD, Shrimati Shetty, PhD, Sukesh Chandran Nair, MD, Biju George, DM, Vikram Mathews, MD, Alok Srivastava, MD, FRACP,FRCPA

Blood (2018) 132 (Supplement 1): 2494.

https://doi.org/10.1182/blood-2018-99-119279

Published: 2018

Journal Articles

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Louis M. Aledort, MD, Nisha Jain, MBBS,MD, Nanxin Li, Sangeeta Krishnan, PharmD, Benjamin Hagberg, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2018-99-114905

Published: 2018

Journal Articles

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Nanxin Li, Koo Wilson, Marc Botteman, MS, MA, Daniel Nicoloso, Sangeeta Krishnan, PharmD, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3520.

https://doi.org/10.1182/blood-2018-99-114993

Published: 2018

Journal Articles

Perioperative Management of Hemophilia a Using Recombinant Factor VIII in Patients Undergoing Major or Minor Surgery

Atsushi Okamoto, MD, Kenta Yamamoto, Go Eguchi, Yoshitaka Kanai, Terufumi Yamaguchi, Yasuhiro Maeda, MD PhD

Blood (2018) 132 (Supplement 1): 5082.

https://doi.org/10.1182/blood-2018-99-115755

Published: 2018

Journal Articles

Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure

Manuel Carcao, Amy Shapiro, Nina Hwang, Steven Pipe, Sanjay Ahuja, Kenneth Lieuw, MD PhD, Janice Staber, Haowei Linda Sun, Hilda Ding, Michael Wang, Macgregor Steele, Elisa Tsao, Jing Feng, Zahra Al-Khateeb, Jennifer Dumont, Nisha Jain

Blood (2018) 132 (Supplement 1): 2500.

https://doi.org/10.1182/blood-2018-99-110467

Published: 2018

Journal Articles

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Beatrice Nolan, Johnny Mahlangu, Guy Young, Barbara A Konkle, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Johannes Oldenburg, MD PhD, Keiji Nogami, MDPhD, Nikola Tripkovic, Huixing Yuan, Dan Rudin

Blood (2018) 132 (Supplement 1): 1192.

https://doi.org/10.1182/blood-2018-99-118586

Published: 2018

Journal Articles

Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada

Haowei Linda Sun, MD FRCPC, Ming Yang, PhD, Man-Chiu Poon, MD, Adrienne Lee, MD, Katherine Sue Robinson, MD, Michelle Sholzberg, MDM, MSc, FRCPC, John K. Wu, MBBS, FRCPC, MS, Alfonso Iorio, MD PhD, Victor S. Blanchette, FRCP, Robert J Klaassen, MD FRCPC, Shannon Jackson, MD FRCPC

Blood (2018) 132 (Supplement 1): 4813.

https://doi.org/10.1182/blood-2018-99-113858

Published: 2018

Journal Articles

Bilateral, Simultaneous Total Knee Replacement (TKR) Surgery for Hemophilia a with Eloctate (Extended Half Life Product)—A Feasible and Cost Effective Approach

Shashikant Apte, MD FRCPA, Rajesh Phatale, MD, Aditi Joshi, BAMS, Kannan Subramanian, MD DM, MBBS

Blood (2018) 132 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2018-99-116160

Published: 2018

Journal Articles

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer

Barbara A Konkle, Amy Shapiro, Doris Quon, Janice Staber, Takashi Suzuki, MD PhD, Stacey Poloskey, Kara Rice, Suresh Katragadda, Dan Rudin, Joachim Fruebis

Blood (2018) 132 (Supplement 1): 636.

https://doi.org/10.1182/blood-2018-99-113575

Published: 2018

Journal Articles

Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors

Patrick T. Ebbert, BS, Margaret V. Ragni, MD MPH, Frederico Xavier, MD MS, Lynn M. Malec, MD, Craig D. Seaman

Blood (2017) 130 (Supplement 1): 3689.

https://doi.org/10.1182/blood.V130.Suppl_1.3689.3689

Published: 2017

Journal Articles

Clinical Outcomes of Weekly Prophylaxis with rFVIIIFc: Longitudinal Analysis of the A-LONG and ASPIRE Study Population

Amy D. Shapiro, MD, Alok Srivastava, MD, Margaret V. Ragni, MD MPH, Ingrid Pabinger, MD, Stefan Lethagen, Elisa Tsao, Desilu Glazebrook, Doris Quon

Blood (2017) 130 (Supplement 1): 2368.

https://doi.org/10.1182/blood.V130.Suppl_1.2368.2368

Published: 2017

Journal Articles

Generation of FVIII-Specific Tregs Expressing a Chimeric Antigen Receptor (CAR) to Suppress Inhibitor Development in Hemophilia a Mice

Moanaro Biswas, PhD, Todd M Brusko, PhD, Roland W Herzog, PhD

Blood (2017) 130 (Supplement 1): 176.

https://doi.org/10.1182/blood.V130.Suppl_1.176.176

Published: 2017

Journal Articles

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Sri Adapa, BSPharm, MBA, Olga Ovcinnikova, MSc, Ian Leighton, PhD, Shamika de Silva, PhD, Matthew Bending, PhD, Larisa Belyanskaya, PhD, Cosentino Lidia, PhD, Anne Myerson, MSc

Blood (2017) 130 (Supplement 1): 4929.

https://doi.org/10.1182/blood.V130.Suppl_1.4929.4929

Published: 2017

Journal Articles

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a

Barbara Konkle, MD, K John Pasi, David J Perry, Johnny Mahlangu, Savita Rangarajan, Simon A Brown, Hideji Hanabusa, Ingrid Pabinger, Lynda M Cristiano, Elisa Tsao, Bent Winding, Desilu Glazebrook, Stefan Lethagen, Shannon Jackson

Blood (2016) 128 (22): 1413.

https://doi.org/10.1182/blood.V128.22.1413.1413

Published: 2016

Journal Articles

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Children with Severe Hemophilia a

Guy Young, Raina Liesner, K John Pasi, Beatrice Nolan, Stefan Lethagen, Lynda M Cristiano, Elisa Tsao, Bent Winding, Johnny Mahlangu

Blood (2016) 128 (22): 1414.

https://doi.org/10.1182/blood.V128.22.1414.1414

Published: 2016

Journal Articles

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

Michael Wang, MD, K John Pasi, Ingrid Pabinger, Prof, Bryce A. Kerlin, Roshni Kulkarni, MD, Beatrice Nolan, Raina Liesner, Simon A Brown, Hideji Hanabusa, Elisa Tsao, Bent Winding, Stefan Lethagen, Nisha Jain

Blood (2016) 128 (22): 3791.

https://doi.org/10.1182/blood.V128.22.3791.3791

Published: 2016

NARROW

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Phase 1 Repeat Dosing with BIVV001: The First Investigational Factor VIII Product to Break through the Von Willebrand Factor-Imposed Half-Life Ceiling

Cryo-EM Structure of BIVV001 Reveals Coagulation Factor VIII-Von Willebrand Factor D'D3 Interaction Mode

Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein

Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate — Recombinant Factor VIII Fc (Eloctate™) — a Report from India

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Perioperative Management of Hemophilia a Using Recombinant Factor VIII in Patients Undergoing Major or Minor Surgery

Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada

Bilateral, Simultaneous Total Knee Replacement (TKR) Surgery for Hemophilia a with Eloctate (Extended Half Life Product)—A Feasible and Cost Effective Approach

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer

Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors

Clinical Outcomes of Weekly Prophylaxis with rFVIIIFc: Longitudinal Analysis of the A-LONG and ASPIRE Study Population

Generation of FVIII-Specific Tregs Expressing a Chimeric Antigen Receptor (CAR) to Suppress Inhibitor Development in Hemophilia a Mice

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Children with Severe Hemophilia a

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only